JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Atorvastatin exists in four optical forms. The (3R, 5R)-atorvastatin enantiomer displays the greatest activity against HMG-CoA reductase. (3S,5S)-Atorvastatin is an enantiomer of atorvastatin with little or no inhibitory activity against HMG-CoA reductase [1]. Atorvastatin is a synthetic HMG-CoA reductase inhibitor implicated in lowering plasma cholesterol levels by inhibiting endogenous cholesterol synthesis. Atorvastatin also reduces triglyceride levels through an as yet unproven mechanism [2]. In various trials in patients with hypercholesterolaemia, atorvastatin produced greater reductions in total cholesterol, apolipoprotein B, LDL-cholesterol and triglyceride levels. In patients with primary hypercholesterolaemia, atorvastatin in combination with colestipol produced significant reductions in LDL-cholesterol levels and smaller reductions in triglyceride levels than atorvastatin monotherapy [2].
References:[1] Kocarek T A, Dahn M S, Cai H, et al. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes[J]. Drug Metabolism and Disposition, 2002, 30(12): 1400-1405.[2] Lea A P, McTavish D. Atorvastatin[J]. Drugs, 1997, 53(5): 828-847.